Letizia Santinelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Letizia Santinelli has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Alexander Zimprich
Comprehensive Center for Clinical Neurosciences and Mental Health Medical University of Vienna Vienna Austria
1 shared publication- Annika Hajosch
Department of Neurosurgery, Ulm University Medical Center, 89081 Ulm, Germany
1 shared publication - Christian Rainer Wirtz
Department of Neurosurgery, Ulm University Medical Center, 89081 Ulm, Germany
1 shared publication Christine Klein
Institute of Neurogenetics University of Lübeck Lübeck Germany
1 shared publicationChristof Brücke
Comprehensive Center for Clinical Neurosciences and Mental Health Medical University of Vienna Vienna Austria
1 shared publication- Cornelis Blauwendraat
Global Parkinson's Genetics Program, Chevy Chase, MD, USA; Coalition for Aligning Science (CAS), Chevy Chase, MD, USA
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1327
BH3 Profiling Identifies Apoptotic Priming by SREBP-1/-2 Inhibition and Synergistic Anti-Glioblastoma Activity When Combined with ABT-263 In Vitro
Background/Objectives: Glioblastoma exhibits profound therapy resistance driven in part by complex pro-survival signaling. We hypothesized that targeting lipid metabolism via SREBP-1/2 inhibition (fatostatin) might alter the apoptotic phenotype and facilitate an apoptotic response driven by BH3 mimetics (ABT-263) in glioblastoma in vitro. Methods: Dynamic BH3 profiling was performed to detect apoptotic priming. The combined inhibition of SREBP-1/2 and Bcl-xL/Bcl-2 was evaluated across 2- and 3-dimensional culture models. The cell lines used included established cell lines as well as primary cultures and glioma stem-like cells. Extracellular flux analysis was used to assess metabolic effects. Changes in migration were evaluated through time-lapse analysis, scratch, and Transwell assays. Results: BH3 profiling showed that treatment with fatostatin increased Bcl-xL/Bcl-2 reliance, while ABT-263 increased Mcl-1 dependence. The combination showed potent synergy in inhibiting viability and spheroid growth, driven at least in part by enhanced caspase-dependent apoptosis. Mechanistically, fatostatin induced dose-dependent Mcl-1 downregulation, sensitizing cells to ABT-263. Dual treatment suppressed oxidative phosphorylation and impaired cell migration, while exhibiting low toxicity in non-pathological cells. Conclusions: This study indicates that combined inhibition of SREBP-1/2 and Bcl-xL/Bcl-2 represents a promising therapeutic strategy for the treatment of glioblastoma. The efficacy of this dual approach potentially lies in the downregulation of Mcl-1 induced by fatostatin and suppression of oxidative phosphorylation. Further studies are warranted.
- 20 October 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1327
Open AccessBH3 Profiling Identifies Apoptotic Priming by SREBP-1/-2 Inhibition and Synergistic Anti-Glioblastoma Activity When Combined with ABT-263 In Vitro
Background/Objectives: Glioblastoma exhibits profound therapy resistance driven in part by complex pro-survival signaling. We hypothesized that targeting lipid metabolism via SREBP-1/2 inhibition (fatostatin) might alter the apoptotic phenotype and facilitate an apoptotic response driven by BH3 mimetics (ABT-263) in glioblastoma in vitro. Methods: Dynamic BH3 profiling was performed to detect apoptotic priming. The combined inhibition of SREBP-1/2 and Bcl-xL/Bcl-2 was evaluated across 2- and 3-dimensional culture models. The cell lines used included established cell lines as well as primary cultures and glioma stem-like cells. Extracellular flux analysis was used to assess metabolic effects. Changes in migration were evaluated through time-lapse analysis, scratch, and Transwell assays. Results: BH3 profiling showed that treatment with fatostatin increased Bcl-xL/Bcl-2 reliance, while ABT-263 increased Mcl-1 dependence. The combination showed potent synergy in inhibiting viability and spheroid growth, driven at least in part by enhanced caspase-dependent apoptosis. Mechanistically, fatostatin induced dose-dependent Mcl-1 downregulation, sensitizing cells to ABT-263. Dual treatment suppressed oxidative phosphorylation and impaired cell migration, while exhibiting low toxicity in non-pathological cells. Conclusions: This study indicates that combined inhibition of SREBP-1/2 and Bcl-xL/Bcl-2 represents a promising therapeutic strategy for the treatment of glioblastoma. The efficacy of this dual approach potentially lies in the downregulation of Mcl-1 induced by fatostatin and suppression of oxidative phosphorylation. Further studies are warranted.
- Open Access
- 30 March 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (6) , 1605-1608
Lack of Cerebrospinal Fluid α‐Synuclein Seeding in VPS35 D620N ‐ and LRRK2 Y1699C ‐Linked Parkinson's Disease
- 30 March 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (6) , 1605-1608
Open AccessLack of Cerebrospinal Fluid α‐Synuclein Seeding in VPS35 D620N ‐ and LRRK2 Y1699C ‐Linked Parkinson's Disease